New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

BioVie Inc. (BIVI) vs Lexaria Bioscience Corp. (LEXX)

BioVie Inc. and Lexaria Bioscience Corp. are both Biotechnology companies. BioVie Inc. and Lexaria Bioscience Corp. are of similar size ($9.8M and $9.5M). BioVie Inc. has the higher net margin (0.00% vs −1,686.1%) and the higher return on invested capital (0.00% vs −662.6%). Across the 12 metrics below, BioVie Inc. leads on 8 and Lexaria Bioscience Corp. on 4.

Valuation

Metric BIVI LEXX Biotechnology median
P/E n/m n/m 8.49
P/S — 12.30 8.56
P/B 1.00 1.53 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA 0.05 n/m 0.69
EV/Sales — 5.63 8.00
Earnings yield (360.76%) (129.52%) (35.81%)
Free cash flow yield (289.42%) (112.89%) (25.41%)

Profitability

Metric BIVI LEXX Biotechnology median
Gross margin — 99.62% 70.18%
Operating margin 0.00% (1,683.06%) 0.00%
Net margin 0.00% (1,686.05%) 0.00%
Free cash flow margin 0.00% (1,494.56%) 0.00%
Return on equity (143.66%) (162.60%) (51.58%)
Return on assets (119.34%) (134.20%) (45.91%)
Return on invested capital 0.00% (662.56%) 0.00%

Growth

Metric BIVI LEXX Biotechnology median
Revenue growth (TTM) — 52.04% 7.20%
EPS growth (last fiscal year) 74.83% (40.43%) 29.04%
Revenue growth, 5-year CAGR — 17.53% 9.54%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric BIVI LEXX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.40 10.60 4.79
Net debt to EBITDA 0.40 0.17 1.01

Dividend

Metric BIVI LEXX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric BIVI LEXX Biotechnology median
Market cap 9.76m 9.46m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack